Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2006 1
2007 1
2008 2
2009 1
2010 1
2011 2
2012 2
2014 1
2021 1
2022 2
2023 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean thoa n (87 results)?
Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn's Disease Commencing Biological Therapy: The Motility Study.
Plumb AA, Moran G, Chowdhury K, Ahmed N, Philpott S, Ahmad T, Bloom S, Hart A, Jacobs I, Menys A, Mooney P, Tolan D, Travis S, Bhagwanani A, Bhatnagar G, Boone D, Franklin J, Gangi-Burton A, Hameed M, Helbren E, Hosseini-Ardehali F, Hyland R, Kilic Y, Kumar S, Lambie H, Mohsin M, Patel A, Rahman S, Sakai N, Sidhu H, Thomson E, Ahmed S, Bannur Chikkeragowda U, Barratt N, Beeston T, Fitzke H, Gibbons N, Godfrey E, Gupta A, Higginson A, Isaac E, Kok KB, Langlands S, Parkes M, Patel J, Patel K, Patel K, Patodi N, Pollok R, Przemiosolo R, Robinson C, Thoua N, Wadke A, Halligan S, Taylor SA; MOTILITY study co-authors. Plumb AA, et al. Among authors: thoua n. Inflamm Bowel Dis. 2025 Sep 1;31(9):2438-2450. doi: 10.1093/ibd/izaf023. Inflamm Bowel Dis. 2025. PMID: 40053679 Free PMC article.
MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease.
Sakai NS, Plumb AA, Ahmed N, Chowdhury K, Kilic Y, Hameed M, Patel A, Bhagwanani A, Helbren E, Hyland R, Bhatnagar G, Sidhu H, Lambie H, Franklin JM, Mohsin M, Thomson E, Boone D, Tolan D, Rahman S, Ding N, Moran GW, Bloom S, Hart A, Menys A, Travis S, Halligan S, Taylor SA; Motility trial investigators. Sakai NS, et al. Insights Imaging. 2025 Mar 19;16(1):61. doi: 10.1186/s13244-025-01930-w. Insights Imaging. 2025. PMID: 40106118 Free PMC article.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421
Treating functional lower gastrointestinal symptoms.
Thoua N, Emmanuel A. Thoua N, et al. Clin Med (Lond). 2006 Sep-Oct;6(5):449-52. doi: 10.7861/clinmedicine.6-5-449. Clin Med (Lond). 2006. PMID: 17080890 Free PMC article. Review. No abstract available.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Lin S, et al. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. Nat Commun. 2022. PMID: 35296643 Free PMC article.
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Liu Z, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. Lancet Gastroenterol Hepatol. 2023. PMID: 36481043 Free PMC article.
17 results